Φορτώνει......
A new paradigm evaluating cost per cure of HCV infection in the UK
BACKGROUND: New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitors (PI) with regard to costs and treatment outcomes are needed. We investigated...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Hepatol Med Policy |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5898515/ https://ncbi.nlm.nih.gov/pubmed/30288304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41124-016-0002-z |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|